Okami Medical announced today that it closed a $32.5 million financing round to support its catheter-based technologies.

Okami Medical今天宣布，它完成了一轮3250万美元的融资，以支持其基于导管的技术。

Aliso Viejo, California-based Okami develops multiple technologies for peripheral vascular occlusion. To date, it developed the LOBO (low-profile braided occluder) vascular occlusion system and the Sendero microcatheter.

加利福尼亚州Aliso Viejo的Okami开发了多种外周血管闭塞技术。迄今为止，它开发了LOBO（低轮廓编织封堵器）血管闭塞系统和Sendero微导管。

LOBO provides interventional physicians with a single-device, one-and-done solution for occluding a wide range of arterial targets. It also eliminates the need for multiple embolic devices. Its proprietary HDBraid technology creates a highly occlusive pore structure that substantially reduces blood flow and accelerates vessel closure.

LOBO为介入医生提供了一种单一设备，一种彻底的解决方案，用于阻塞各种动脉靶点。它还消除了对多个栓塞装置的需求。其专有的HDBraid技术产生了高度闭塞的孔隙结构，可大大减少血流并加速血管闭合。

The platform enables the fast and efficient closure of blood vessels throughout the body to help treat a diverse set of conditions..

该平台能够快速有效地关闭全身血管，以帮助治疗各种疾病。。

Sendero enables the smooth delivery of interventional devices while providing optimal trackability through tortuous peripheral vessels. Okami designed the FDA-cleared system for the delivery of LOBO-3 and LOBO-5 devices. The system incorporates a hydrophilic coating, stainless steel braid and radiopaque market band.

Sendero能够顺利交付介入设备，同时通过曲折的外围血管提供最佳跟踪能力。Okami设计了FDA批准的LOBO-3和LOBO-5设备交付系统。该系统包含亲水涂层、不锈钢编织带和不透射线的市场波段。

This optimizes trackability and enables the precise placement of interventional devices. Meanwhile, a lubricious PTFE inner liner allows for the low-friction delivery of interventional devices..

这优化了可追踪性，并能够精确放置介入设备。同时，有色PTFE内衬允许介入装置的低摩擦输送。。

New investor Vensana Capital led the financing. Existing investors, including U.S. Venture Partners, members of the Okani board and other industry veterans, also joined in.

新投资者Vensana Capital主导了融资。包括美国风险投资伙伴、Okani董事会成员和其他行业资深人士在内的现有投资者也加入了进来。

“We are honored to have the support of Vensana and our existing investors to advance these important technologies and deliver them to patients,” said Rhonda Robb, president and CEO of Okami. “We are also grateful for the support and contributions of our employees and physician partners as we work tirelessly to build the market leader in vascular occlusion.”.

Okami总裁兼首席执行官朗达·罗伯（RhondaRobb）表示：“我们很荣幸能得到文萨纳（Vensana）和现有投资者的支持，推动这些重要技术的发展，并将其交付给患者。”。“我们也感谢我们的员工和医生合作伙伴的支持和贡献，因为我们不懈地努力建立血管闭塞领域的市场领导者。”。